Astrazeneca stock closed lower, but analysts project favorable outlook and growth potential.

From Nasdaq: 2025-06-02 18:15:00

Astrazeneca (AZN) closed at $71.93, down 1.24% from the previous day. The stock underperformed the S&P 500, which gained 0.41%. Astrazeneca’s recent estimates project earnings of $1.11 per share and quarterly revenue of $14.03 billion. Analyst estimates and Zacks Rank indicate favorable outlook and momentum for the company.

The Medical sector saw Astrazeneca’s shares rise 0.54% in the past month. Analysts expect earnings of $4.49 per share and revenue of $57.68 billion for the full year. Astrazeneca holds a Zacks Rank of #3 (Hold), with a Forward P/E ratio of 16.2 and a PEG ratio of 1.34, showing valuation and growth potential.

Zacks identifies a top semiconductor stock with significant growth potential, catering to the demand for AI, ML, and IoT. The global semiconductor market is expected to grow from $452 billion in 2021 to $803 billion by 2028. Investors can access free reports and stock analysis on AstraZeneca and other top stocks through Zacks Investment Research.



Read more at Nasdaq: Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors